Anuh Pharma Limited (506260) Fair Value & Analysis
Healthcare · IN · Market cap ₹8.4B
Fair value as of: Jul 4, 2026
From 17 valuation models · updated today
Share price +4.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹67.12 – ₹108.57 · fair‑value band ₹72.64 – ₹192.26 · the ₹80.21 price screens below the ₹110.37 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Anuh Pharma Limited (506260) currently trades at ₹80.21, while our model-based Fair Value estimate is ₹110.37 — implying the stock looks roughly 37.6% undervalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Anuh Pharma Limited generated revenue of ₹3.9B at a net margin of 7.4%. Revenue grew 55.9% year over year. It earns a return on equity of 16.4%. Net debt stands at ₹114M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Anuh Pharma Limited manufactures and sells pharmaceuticals, medicinal chemicals, and botanical products in India. The company offers active pharmaceutical ingredients, such as macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, and expectorant, quinolones, and intermediates. It also provides corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, and anti-histamines. The company also exports its products. Anuh Pharma Limited was founded in 1960 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Anuh Pharma Limited reported revenue of ₹7.7B in FY2026 versus ₹4.9B in FY2022, a compound +12.2%/yr. Reported net income was ₹410M in FY2026, compounding +7.7%/yr from FY2022.
Is 506260 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹244.55 | ₹96.79 | -60% |
| Medicamen Biotech Limited 531146 | ₹262.00 | ₹98.91 | -62% |
| Coral Laboratories Limited 524506 | ₹605.55 | ₹779.49 | +29% |
| Gennex Laboratories Limited 531739 | ₹10.16 | ₹28.19 | +177% |
| Lactose (India) Limited 524202 | ₹103.75 | ₹130.91 | +26% |
| Beryl Drugs Limited 524606 | ₹21.22 | ₹17.12 | -19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Anuh Pharma Limited (506260) undervalued?
What is the fair value of 506260?
What is the quality score of 506260?
What is the revenue of Anuh Pharma Limited (506260)?
What is the net profit margin of 506260?
Does Anuh Pharma Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.